APT-1011 is a treatment for eosinophilic esophagitis, a condition that currently faces an unmet medical need. The medication was originally developed by TPG Capital, but they created a new company, Ellodi Pharmaceuticals, to continue their research.
About Eosinophilic Esophagitis (EoE)
EoE is a condition that is characterized by excess eosinophils in the esophagus. These high levels may be due to a hypersensitivity to a food or allergen, or medical professionals suspect that the eotaxin-3 gene could play a role. Regardless of the cause, this condition causes symptoms like nausea, vomiting, food getting stuck in the throat, difficulty swallowing, stomach pain, loss of appetite, malnutrition, weight loss, and poor growth. Removing milk, soy, nuts, wheat, fish, and eggs from the diet has been shown to improve these symptoms. If there is a severe reaction, affected individuals may need to use a feeding tube with a liquid diet and take steroids to manage the inflammation.
APT-1011 is a novel, oral form of fluticasone that is meant to be topically applied to the esophagus without remaining in the mouth for a long time. Studies have shown that it is able to reduce the number of eosinophils in the esophagus. It is currently being evaluated in the FLUTE trials, which study how APT-1011 manages EoE in children, adolescents, and adults.
Ellodi Pharmaceuticals to Develop APT-1011
Ellodi Pharmaceuticals was created by TPG to continue the development of APT-1011. This decision was made after TPG sold another one of their pharmaceutical companies, Adare. While they sold the microbiome businesses and technology to two other companies, Thomas H. Lee Partners and Frazier Healthcare Partners, they retained the rights to APT-1011.
The head of Adare, Troy Hamilton, will take on the role of CEO at Ellodi. Hopefully this means that there will be a smooth transition, and APT-1011 will be developed with no issues. As EoE patients face an unmet medical need, the approval of this treatment could improve the lives of many.
Find the source article here.